William E Smoyer

List of Publications by Year
in descending order

55 papers	2,000 citations	257450 24 h-index	254184 43 g-index
58 all docs	58 docs citations	58 times ranked	2647 citing authors

#	Article	IF	Citations
1	Using a Multi-Institutional Pediatric Learning Health System to Identify Systemic Lupus Erythematosus and Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 65-74.	4.5	24
2	Advances in proteomic profiling of pediatric kidney diseases. Pediatric Nephrology, 2022, 37, 2255-2265.	1.7	10
3	Utility of the 2018 revised ISN/RPS thresholds for glomerular crescents in childhood-onset lupus nephritis: a Pediatric Nephrology Research Consortium study. Pediatric Nephrology, 2022, 37, 3139-3145.	1.7	3
4	Innovating and invigorating the clinical trial infrastructure for glomerular diseases. Kidney International, 2021, 99, 519-523.	5.2	4
5	A pediatric gateway initiative for glomerular disease: introducing PIONEER. Kidney International, 2021, 99, 515-518.	5.2	4
6	SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Pediatric Research, 2021, 90, 966-970.	2.3	27
7	Results of the PROPINE randomized controlled trial: determining the ever-elusive target, the optimal plan for relapses of nephrotic syndrome in children. Kidney International, 2021, 99, 311-313.	5.2	0
8	Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney International Reports, 2021, 6, 785-795.	0.8	7
9	Evaluation of the Reproductive Care Provided to Adolescent Patients in Nephrology Clinics: A Pediatric Nephrology Research Consortium Study. Kidney International Reports, 2021, 6, 1411-1415.	0.8	5
10	Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thrombosis Research, 2021, 201, 50-59.	1.7	13
11	Improving data quality in observational research studies: Report of the Cure Glomerulonephropathy (CureGN) network. Contemporary Clinical Trials Communications, 2021, 22, 100749.	1.1	7
12	Biomarkers in pediatric glomerulonephritis and nephrotic syndrome. Pediatric Nephrology, 2021, 36, 2659-2673.	1.7	4
13	Challenges of access to kidney care for children in low-resource settings. Nature Reviews Nephrology, 2021, 17, 33-45.	9.6	28
14	Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Proteomics. Kidney International Reports, 2020, 5, 66-80.	0.8	34
15	Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Metabolomics. Kidney International Reports, 2020, 5, 81-93.	0.8	28
16	Dyslipidemia and cardiovascular health in childhood nephrotic syndrome. Pediatric Nephrology, 2020, 35, 1601-1619.	1.7	21
17	Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children. Kidney International Reports, 2020, 5, 2313-2324.	0.8	14
18	Renal Survival in Children with Glomerulonephritis with Crescents: A Pediatric Nephrology Research Consortium Cohort Study. Journal of Clinical Medicine, 2020, 9, 2385.	2.4	12

#	Article	IF	Citations
19	IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatric Nephrology, 2020, 35, 1529-1561.	1.7	179
20	Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?. Kidney International, 2020, 97, 1104-1106.	5.2	4
21	Rituximab Use in the Management of Childhood Nephrotic Syndrome. Frontiers in Pediatrics, 2019, 7, 178.	1.9	33
22	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
23	Using Electronic Health Record Data to Rapidly Identify Children with Glomerular Disease for Clinical Research. Journal of the American Society of Nephrology: JASN, 2019, 30, 2427-2435.	6.1	29
24	Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatric Nephrology, 2019, 34, 261-267.	1.7	29
25	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	1.9	68
26	Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nature Reviews Nephrology, 2018, 14, 57-70.	9.6	192
27	Pharmacological and genetic inhibition of downstream targets of p38 MAPK in experimental nephrotic syndrome. American Journal of Physiology - Renal Physiology, 2018, 314, F602-F613.	2.7	6
28	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39
29	â€œLearn From Every Patientâ€ How a Learning Health System Can Improve Patient Care. Pediatric Quality & Safety, 2018, 3, e100.	0.8	11
30	Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent. Journal of the American Society of Nephrology: JASN, 2017, 28, 2618-2630.	6.1	34
31	Peritoneal Dialysis to Treat Patients with Acute Kidney Injuryâ€"The Saving Young Lives Experience in West Africa: Proceedings of the Saving Young Lives Session at the First International Conference of Dialysis in West Africa, Dakar, Senegal, December 2015. Peritoneal Dialysis International, 2017, 37, 155-158.	2.3	45
32	Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. JAMA Pediatrics, 2017, 171, e172914.	6.2	46
33	Role of albumin and its modifications in glomerular injury. Pflugers Archiv European Journal of Physiology, 2017, 469, 975-982.	2.8	6
34	Enhancing clinical trial development for pediatric kidney diseases. Pediatric Research, 2017, 82, 727-732.	2.3	3
35	â€˜Learn From Every Patientâ€™: implementation and early results of a learning health system. Developmental Medicine and Child Neurology, 2017, 59, 183-191.	2.1	59
36	Creating Local Learning Health Systems. JAMA - Journal of the American Medical Association, 2016, 316, 2481.	7.4	40

#	Article	IF	Citations
37	Glomerular Diseases: Registries and Clinical Trials. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2234-2243.	4.5	11
38	â€œSaving Young Livesâ€•with acute kidney injury: the challenge of acute dialysis in low-resource settings. Kidney International, 2016, 89, 254-256.	5.2	45
39	Activation of the IL-2 Receptor in Podocytes: A Potential Mechanism for Podocyte Injury in Idiopathic Nephrotic Syndrome?. PLoS ONE, 2016, 11, e0157907.	2.5	13
40	Development of a pediatric-specific clinical probability tool for diagnosis of venous thromboembolism: a feasibility study. Pediatric Research, 2015, 77, 463-471.	2.3	22
41	Sponsors meet scientists to speed pediatric medicines development. Science Translational Medicine, 2015, 7, 279fs11.	12.4	3
42	Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2015, 26, 3009-3019.	6.1	23
43	Saving Young Lives: provision of acute dialysis in low-resource settings. Lancet, The, 2015, 386, 2056.	13.7	30
44	Healthcare burden of venous thromboembolism in childhood chronic renal diseases. Pediatric Nephrology, 2015, 30, 829-837.	1.7	19
45	HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2015, 26, 1701-1710.	6.1	118
46	Albumin-induced podocyte injury and protection are associated with regulation of COX-2. Kidney International, 2014, 86, 1150-1160.	5.2	50
47	Venous thromboembolism in pediatric nephrotic syndrome. Pediatric Nephrology, 2014, 29, 989-997.	1.7	69
48	Endogenous Thrombin Potential is Directly Correlated with Proteinuria Severity in Both Nephrotic Syndrome Patients and an Animal Model of Nephrotic Syndrome. Blood, 2014, 124, 4243-4243.	1.4	1
49	Thrombin Induces Apoptosis in Human and Rat Podocytes in a Protease Activated Receptor (PAR)-Dependent Manner. Blood, 2014, 124, 2808-2808.	1.4	0
50	Thrombin Generation Is Directly Correlated To Proteinuria Severity In An Experimental Model Of Nephrotic Syndrome. Blood, 2013, 122, 3615-3615.	1.4	0
51	Epidemiology and Pathophysiology of Nephrotic Syndromeâ€“Associated Thromboembolic Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 513-520.	4.5	256
52	Childhood nephrotic syndromeâ€”current and future therapies. Nature Reviews Nephrology, 2012, 8, 445-458.	9.6	85
53	Comparison of Direct Action of Thiazolidinediones and Glucocorticoids on Renal Podocytes: Protection from Injury and Molecular Effects. Molecular Pharmacology, 2011, 80, 389-399.	2.3	29
54	Steroid Sensitive and Steroid Resistant Nephrotic Syndrome. , 2011, , 175-200.		0

#	Article	IF	Citations
55	Epidemiology and Risk Factors for Thromboembolic Complications of Childhood Nephrotic Syndrome: A Midwest Pediatric Nephrology Consortium (MWPNC) Study. Journal of Pediatrics, 2009, 155, 105-110.e1.	1.8	120